Ran Nussbaum Insider Trading $KROS Keros Therapeutics, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Ran Nussbaum.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Ran Nussbaum. Ran Nussbaum is Director in ARQULE INC ($ARQL) and in Eloxx Pharmaceuticals, Inc. ($ELOX) and Director in Eloxx Pharmaceuticals, Inc. ($ELOX) and Director in Kite Pharma, Inc. ($KITE) and Director in Keros Therapeutics, Inc. ($KROS) and Director in UroGen Pharma Ltd. ($URGN) and Director in Prevail Therapeutics Inc. ($PRVL).
Ran Nussbaum in Keros Therapeutics, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Ran Nussbaum: Director
Holdings: 2,288,151 shares
Latest Transaction: Nov 19 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Ran Nussbaum in Keros Therapeutics, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ARQL, ELOX, KROS, KITE, PRVL, URGN
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 19 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 50.00 | 6,000 | 300,000 | 155,262 | 149.3 K to 155.3 K (+4.02 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 50.00 | 14,400 | 720,000 | 1,228,326 | 1.2 M to 1.2 M (+1.19 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 50.00 | 12,966 | 648,300 | 1,122,768 | 1.1 M to 1.1 M (+1.17 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 50.00 | 26,634 | 1,331,700 | 2,288,151 | 2.3 M to 2.3 M (+1.18 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 36,858 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 79,653 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 88,460 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 163,612 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 68,654 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 91,538 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 82,425 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 169,307 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 737,226 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 663,825 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 1,363,542 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 43,750 | 700,000 | 149,262 | 105.5 K to 149.3 K (+41.46 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 105,000 | 1,680,000 | 1,213,926 | 1.1 M to 1.2 M (+9.47 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 94,546 | 1,512,736 | 1,109,802 | 1 M to 1.1 M (+9.31 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 194,203 | 3,107,248 | 2,261,517 | 2.1 M to 2.3 M (+9.39 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 36,858 | 0 | 105,512 | 68.7 K to 105.5 K (+53.69 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 79,653 | 0 | 1,108,926 | 1 M to 1.1 M (+7.74 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 88,460 | 0 | 1,015,256 | 926.8 K to 1 M (+9.54 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 163,612 | 0 | 2,067,314 | 1.9 M to 2.1 M (+8.59 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 68,654 | 0 | 68,654 | 0 to 68.7 K |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 91,538 | 0 | 1,029,273 | 937.7 K to 1 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 82,425 | 0 | 926,796 | 844.4 K to 926.8 K (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 169,307 | 0 | 1,903,702 | 1.7 M to 1.9 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 737,226 | 0 | 937,735 | 200.5 K to 937.7 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 663,825 | 0 | 844,371 | 180.5 K to 844.4 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 1,363,542 | 0 | 1,734,395 | 370.9 K to 1.7 M (+367.68 %) |
Page: 1